Options of fertility preservation in female cancer patients

Obstetrical and Gynecological Survey

Volumn 65, Issue 8, 2010, Pages 531-542

  Oktem, Ozgur ^a   Urman, Bulent ^a  

^a AMERICAN HOSPITAL   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

AFLIBERCEPT; ALEMTUZUMAB; AMINOLEVULINIC ACID; ANAGRELIDE; ANTHRACYCLINE; ARSENIC TRIOXIDE; AZIRIDINE DERIVATIVE; BLEOMYCIN; CAMPTOTHECIN; CHLORMETHINE; DACTINOMYCIN; EFAPROXIRAL; ETOPOSIDE; FLAVOPIRIDOL; FOLIC ACID; HYDRAZINE DERIVATIVE; NITROSOUREA; PLATINUM; PROTEIN TYROSINE KINASE INHIBITOR; PURINE DERIVATIVE; PYRIMIDINE; RETINOID; ROSCOVITINE; SULFONIC ACID DERIVATIVE; TAXANE DERIVATIVE; TRIAZINE DERIVATIVE; UNINDEXED DRUG; VINBLASTINE; VINCRISTINE;

ADVERSE OUTCOME; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER RADIOTHERAPY; CRYOPRESERVATION; FEMALE FERTILITY; FREEZING; GONADOTOXICITY; HUMAN; NONHUMAN; OVARIAN PRESERVATION; OVARIOPEXY; PREMATURE OVARIAN FAILURE; REPRODUCTIVE TOXICITY; REVIEW; TISSUE TRANSPLANTATION; UNSPECIFIED SIDE EFFECT; VITRIFICATION;

ANIMALS; ANTINEOPLASTIC AGENTS; CRYOPRESERVATION; FEMALE; FERTILITY; HUMANS; INFERTILITY, FEMALE; NEOPLASMS; PREGNANCY; RADIOTHERAPY; REPRODUCTIVE TECHNIQUES, ASSISTED;

EID: 78049372786     PISSN: 00297828     EISSN: 15339866     Source Type: Journal    
DOI: 10.1097/OGX.0b013e3181f8c0aa     Document Type: Review

References (84)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2009. CA Cancer J Clin 2009;59:225-249.
2. Oktay K, Oktem O. Fertility preservation medicine: a new field in the care of young cancer survivors. Pediatr Blood Cancer 2009;53:267-273.
3. Lee SJ, Schover LR, Partridge AH, et al. American Society of Clinical Oncology recommendations on fertility preservation in cancer patients. J Clin Oncol 2006;24:2917-2931.
4. Oktem O, Oktay K. Quantitative assessment of the impact of chemotherapy on ovarian follicle reserve and stromal function. Cancer 2007;110:2222-2229. (Pubitemid 350100744)
5. Oktem O, Oktay K. A novel ovarian xenografting model to characterize the impact of chemotherapy agents on human primordial follicle reserve. Cancer Res 2007;67:10159-10162.
6. Bines J, Oleske DM, Cobleigh MA. Ovarian function in pre-menopausal women treated with adjuvant chemotherapy for breast cancer. J Clin Oncol 1996;14:1718-1729.
7. Reh A, Oktem O, Oktay K. Impact of breast cancer chemotherapy on ovarian reserve: a prospective observational analysis by menstrual history and ovarian reserve markers. Fertil Steril 2008;90:1635-1639.
8. Oktay K, Oktem O, Reh A, et al. Measuring the impact of chemotherapy on fertility in women with breast cancer. J Clin Oncol 2006;24:4044-4046. (Pubitemid 46630768)
9. Lie Fong S, Laven JS, Hakvoort-Cammel FG, et al. Assessment of ovarian reserve in adult childhood cancer survivors using anti-Mullerian hormone. Hum Reprod 2009;24:982-990.
10. Scheffer GJ, Broekmans FJ, Looman CW, et al. The number of antral follicles in normal women with proven fertility is the best reflection of reproductive age. Hum Reprod 2003;18: 700-706.
11. Plowchalk DR, Mattison DR. Phosphoramide mustard is responsible for the ovarian toxicity of cyclophosphamide. Toxi-col Appl Pharmacol 1991;107:472-481.
12. Oktem O, Oktay K. Stem cells: a perspective on oocytes. Ann NY Acad Sci 2008;1127:20-26.
13. Stearns V, Schneider B, Henry NL, et al. Breast cancer treatment and ovarian failure: risk factors and emerging genetic determinants. Nat Rev Cancer 2006;6:886-893.
14. Parulekar WR, Day AG, Ottaway JA, et al. Incidence and prognostic impact of amenorrhea during adjuvant therapy in high-risk premenopausal breast cancer: analysis of a National Cancer Institute of Canada Clinical Trials Group Study-NCIC CTG MA. 5. J Clin Oncol 2005;23:6002-6008.
15. Hortobagyi GN, Buzdar AU, Marcus CE, et al. Immediate and long-term toxicity of adjuvant chemotherapy regimens containing doxorubicin in trials at M.D. Anderson Hospital and Tumor Institute. NCI Monogr 1986;1:105-109.
16. Tham YL, Sexton K, Weiss H, et al. The rates of chemotherapy-induced amenorrhea in patients treated with adjuvant doxorubicin and cyclophosphamide followed by a taxane. Am J Clin Oncol 2007;30:126-132.
17. Oktem O, Oktay K. Preservation of menstrual function in adolescent and young females. Ann NY Acad Sci 2008;1135: 237-243.
18. Brachet C, Heinrichs C, Tenoutasse S, et al. Children with sickle cell disease: growth and gonadal function after hema-topoietic stem cell transplantation. J Pediatr Hematol Oncol 2007;29:445-450.
19. Oktay K, Sonmezer M, Oktem O, et al. Absence of conclusive evidence for the safety and efficacy of gonadotropin-releasing hormone analogue treatment in protecting against chemotherapy-induced gonadal injury. Oncologist 2007;12:1055-1066.
20. Perez-Fidalgo JA, Rosello S, Garcia-Garre E, et al. Incidence of chemotherapy-induced amenorrhea in hormone-sensitive breast cancer patients: the impact of addition of taxanes to anthracycline-based regimens. Breast Cancer Res Treat 2010;120:245-251.
21. Abusief ME, Missmer SA, Ginsburg ES, et al. The effects of paclitaxel, dose density, and trastuzumab on treatment-related amenorrhea in premenopausal women with breast cancer. Cancer 2010;116:791-798.
22. Maneschi F, Benedetti-Panici P, Scambia G, et al. Menstrual and hormone patterns in women treated with high-dose cis-platin and bleomycin. Gynecol Oncol 1994;54:345-348.
23. Kang H, Kim TJ, Kim WY, et al. Outcome and reproductive function after cumulative high-dose combination chemotherapy with bleomycin, etoposide and cisplatin (BEP) for patients with ovarian endodermal sinus tumor. Gynecol Oncol 2008; 111:106-110.
24. Wallace WH, Shalet SM, Crowne EC, et al. Gonadal dysfunction due to cis-platinum. Med Pediatr Oncol 1989;17:409-413.
25. Stillman RJ, Schiff I, Schinfeld J. Reproductive and gonadal function in the female after therapy for childhood malignancy. Obstet Gynecol Surv 1982;37:385-393.
26. Sklar C. Maintenance of ovarian function and risk of premature menopause related to cancer treatment. J Natl Cancer Inst Monogr 2005;34:25-27.
27. Wallace WH, Thomson AB, Kelsey TW. The radiosensitivity of the human oocyte. Hum Reprod 2003;18:117-121.
28. Horning SJ, Hoppe RT, Kaplan HS, et al. Female reproductive potential after treatment for Hodgkin's disease. N Engl J Med 1981;304:1377-1382.
29. Lushbaugh CC, Casarett GW. The effects of gonadal irradiation in clinical radiation therapy: a review. Cancer 1976; 37(suppl 2):1111-1125.
30. Thibaud E, Ramirez M, Brauner R, et al. Preservation of ovarian function by ovarian transposition performed before pelvic irradiation during childhood. J Pediatr 1992;121:880-884.
31. Sarafoglou K, Boulad F, Gillio A, et al. Gonadal function after bone marrow transplantation for acute leukemia during childhood. J Pediatr 1997;130:210-216.
32. Sklar C. Growth and endocrine disturbances after bone marrow transplantation in childhood. Acta Paediatr Suppl 1995; 411:57-61; discussion 62.
33. Sanders JE, Hawley J, Levy W, et al. Pregnancies following high-dose cyclophosphamide with or without high-dose busulfan or total-body irradiation and bone marrow transplantation. Blood 1996;87:3045-3052.
34. Armstrong GT, Whitton JA, Gajjar A, et al. Abnormal timing of menarche in survivors of central nervous system tumors: a report from the Childhood Cancer Survivor Study. Cancer 2009;115:2562-2570.
35. Armstrong GT, Sklar CA, Hudson MM, et al. Long-term health status among survivors of childhood cancer: does sex matter? J Clin Oncol 2007;25:4477-4489.
36. Chow EJ, Friedman DL, Yasui Y, et al. Timing of menarche among survivors of childhood acute lymphoblastic leukemia: a report from the Childhood Cancer Survivor Study. Pediatr Blood Cancer 2008;50:854-858. (Pubitemid 351356099)
37. Wallace WH, Shalet SM, Crowne EC, et al. Ovarian failure following abdominal irradiation in childhood: natural history and prognosis. Clin Oncol (R Coll Radiol) 1989;1:75-79.
38. Bath LE, Wallace WH, Critchley HO. Late effects of the treatment of childhood cancer on the female reproductive system and the potential for fertility preservation. BJOG 2002;109: 107-114.
39. Critchley HO, Wallace WH, Shalet SM, et al. Abdominal irradiation in childhood; the potential for pregnancy. Br J Obstet Gynaecol 1992;99:392-394.
40. Green DM, Whitton JA, Stovall M, et al. Pregnancy outcome of female survivors of childhood cancer: a report from the Childhood Cancer Survivor Study. Am J Obstet Gynecol 2002;187: 1070-1080. (Pubitemid 35178413)
41. Signorello LB, Cohen SS, Bosetti C, et al. Female survivors of childhood cancer: preterm birth and low birth weight among their children. J Natl Cancer Inst 2006;98:1453-1461.
42. Sklar CA, Constine LS. Chronic neuroendocrinological sequelae of radiation therapy. Int J Radiat Oncol Biol Phys 1995;31:1113-1121.
43. Smith AU, Parkes AS. Preservation of ovarian tissue at low temperatures. Lancet 1951;2:570-572.
44. Swearingen RG. Preservation of ovarian tissue in gynecologic surgery. Tex State J Med 1949;45:763-768, illust.
45. Oktay K, Newton H, Aubard Y, et al. Cryopreservation of immature human oocytes and ovarian tissue: an emerging technology? Fertil Steril 1998;69:1-7. (Pubitemid 28075612)
46. Oktay K. Spontaneous conceptions and live birth after hete-rotopic ovarian transplantation: is there a germline stem cell connection? Hum Reprod 2006;21:1345-1348.
47. Donnez J, Dolmans MM, Demylle D, et al. Livebirth after orthotopic transplantation of cryopreserved ovarian tissue. Lancet 2004;364:1405-1410. (Pubitemid 39370715)
48. Meirow D, Levron J, Eldar-Geva T, et al. Pregnancy after transplantation of cryopreserved ovarian tissue in a patient with ovarian failure after chemotherapy. N Engl J Med 2005; 353:318-321.
49. Demeestere I, Simon P, Buxant F, et al. Ovarian function and spontaneous pregnancy after combined heterotopic and or-thotopic cryopreserved ovarian tissue transplantation in a patient previously treated with bone marrow transplantation: case report. Hum Reprod 2006;21:2010-2014.
50. Andersen CY, Rosendahl M, Byskov AG, et al. Two successful pregnancies following autotransplantation of frozen/thawed ovarian tissue. Hum Reprod 2008;23:2266-2272.
51. Silber SJ, DeRosa M, Pineda J, et al. A series of monozygotic twins discordant for ovarian failure: ovary transplantation (cortical vs. microvascular) and cryopreservation. Hum Reprod 2008;23:1531-1537.
52. Oktay K, Oktem O. Ovarian cryopreservation and transplantation for fertility preservation for medical indications: report of an ongoing experience. Fertil Steril 2010;93:762-768.
53. Baird DT, Webb R, Campbell BK, et al. Long-term ovarian function in sheep after ovariectomy and transplantation of autografts stored at-196°C. Endocrinology 1999;140:462-471.
54. Oktay K. Ovarian tissue cryopreservation and transplantation: preliminary findings and implications for cancer patients. Hum Reprod Update 2001;7:526-534.
55. Demeestere I, Simon P, Emiliani S, et al. Orthotopic and heterotopic ovarian tissue transplantation. Hum Reprod Update 2009;15:649-665.
56. Oktay K, Karlikaya GG, Aydin BA. Ovarian cryopreservation and transplantation: basic aspects. Mol Cell Endocrinol 2000; 169:105-108.
57. Isachenko E, Isachenko V, Nawroth F, et al. Human ovarian tissue preservation: is vitrification acceptable method for assisted reproduction? Cryo Letters 2008;29:301-314.
58. Keros V, Xella S, Hultenby K, et al. Vitrification versus controlled-rate freezing in cryopreservation of human ovarian tissue. Hum Reprod 2009;24:1670-1683.
59. Oktem O, Alper E, Peker K, et al. Vitrified human ovaries harbor less primordial follicles and produce less antimullerian hormone (AMH) than slow frozen ovaries. Fertil Steril 2009;92: S65-S66.
60. Trounson A, Mohr L. Human pregnancy following cryopreservation, thawing and transfer of an eight-cell embryo. Nature 1983;305:707-709.
61. Ata B, Chian RC, Tan SL, et al. Cryopreservation of oocytes and embryos for fertility preservation for female cancer patients. Best Pract Res Clin Obstet Gynaecol 2010;24:101-112.
62. Gupta PB, Kuperwasser C. Contributions of estrogen to ER-negative breast tumor growth. J Steroid Biochem Mol Biol 2006;102:71-78.
63. Azim AA, Costantini-Ferrando M, Oktay K. Safety of fertility preservation by ovarian stimulation with letrozole and gonadotropins in patients with breast cancer: a prospective controlled study. J Clin Oncol 2008;26:2630-2635.
64. Chen C. Pregnancy after human oocyte cryopreservation. Lancet 1986;1:884-886.
65. van Uem JF, Siebzehnrubl ER, Schuh B, et al. Birth after cryopreservation of unfertilized oocytes. Lancet 1987;1:752-753.
66. Oktay K, Cil AP, Bang H. Efficiency of oocyte cryopreservation: a meta-analysis. Fertil Steril 2006;86:70-80.
67. Boiso I, Marti M, Santalo J, et al. A confocal microscopy analysis of the spindle and chromosome configurations of human oocytes cryopreserved at the germinal vesicle and metaphase II stage. Hum Reprod 2002;17:1885-1891.
68. Cobo A, Rubio C, Gerli S, et al. Use of fluorescence in situ hybridization to assess the chromosomal status of embryos obtained from cryopreserved oocytes. Fertil Steril 2001;75: 354-360.
69. Stachecki JJ, Munne S, Cohen J. Spindle organization after cryopreservation of mouse, human, and bovine oocytes. Reprod Biomed Online 2004;8:664-672.
70. Chian RC, Huang JY, Gilbert L, et al. Obstetric outcomes following vitrification of in vitro and in vivo matured oocytes. Fertil Steril 2009;91:2391-2398.
71. Noyes N, Porcu E, Borini A. Over 900 oocyte cryopreservation babies born with no apparent increase in congenital anomalies. Reprod Biomed Online 2009;18:769-776.
72. Hamre MR, Robison LL, Nesbit ME, et al. Effects of radiation on ovarian function in long-term survivors of childhood acute lymphoblastic leukemia: a report from the Children's Cancer Study Group. J Clin Oncol 1987;5:1759-1765.
73. Papadakis V, Vlachopapadopoulou E, van Syckle K, et al. Gonadal function in young patients successfully treated for Hodgkin disease. Med Pediatr Oncol 1999;32:366-372.
74. Cowles RA, Gewanter RM, Kandel JJ. Ovarian repositioning in pediatric cancer patients: flexible techniques accommodate pelvic radiation fields. Pediatr Blood Cancer 2007;49:339-341.
75. Meirow D, Nugent D. The effects of radiotherapy and chemotherapy on female reproduction. Hum Reprod Update 2001; 7:535-543.
76. Martin JR, Kodaman P, Oktay K, et al. Ovarian cryopreserva-tion with transposition of a contralateral ovary: a combined approach for fertility preservation in women receiving pelvic radiation. Fertil Steril 2007;87:189.e5-189.e7.
77. Guerrero Urbano MT, Nutting CM. Clinical use of intensity-modulated radiotherapy: part II. Br J Radiol 2004;77:177-182.
78. Ataya K, Pydyn E, Ramahi-Ataya A, et al. Is radiation-induced ovarian failure in rhesus monkeys preventable by luteinizing hormone-releasing hormone agonists? Preliminary observations. J Clin Endocrinol Metab 1995;80:790-795.
79. Blumenfeld Z, Avivi I, Linn S, et al. Prevention of irreversible chemotherapy-induced ovarian damage in young women with lymphoma by a gonadotropin-releasing hormone agonist in parallel to chemotherapy. Hum Reprod 1996;11:1620-1626.
80. Behringer K, Wildt L, Mueller H, et al. No protection of the ovarian follicle pool with the use of GnRH-analogues or oral contraceptives in young women treated with escalated BEACOPP for advanced-stage Hodgkin lymphoma. Final results of a phase II trial from the German Hodgkin Study Group. Ann Oncol. In press.
81. Morita Y, Perez GI, Paris F, et al. Oocyte apoptosis is suppressed by disruption of the acid sphingomyelinase gene or by sphingosine-1-phosphate therapy. Nat Med 2000;6:1109-1114.
82. Paris F, Perez GI, Fuks Z, et al. Sphingosine 1-phosphate preserves fertility in irradiated female mice without propagating genomic damage in offspring. Nat Med 2002;8:901-902.
83. Oktem O, Oktay K. Sphingosine-1-phosphate enhances human primordial follicle survival and blocks ovarian apoptosis in vitro. Fertil Steril 2007;88(suppl 1):S270.
84. Gonfloni S, Di Tella L, Caldarola S, et al. Inhibition of the c-Abl-TAp63 pathway protects mouse oocytes from chemotherapy-induced death. Nat Med 2009;15:1179-1185.